Delonix Bioworks announces the appointment of Rong Xu, Ph.D., as Chief Scientific Officer

Delonix Bioworks has recently appointed Dr. Rong Xu as Chief Scientific Officer (CSO). In this role, Dr. Xu will oversee the vaccine R&D strategy and lead the team in designing and implementing development plans that meet the regulatory requirements of both China and the United States. We are confident that Dr. Xu will guide Delonix on its path to becoming a leading innovative vaccine company at the clinical stage.

Rong Xu, Chief Scientific Officer of Delonix Bioworks

Dr. Rong Xu has extensive work experience in the biotechnology and pharmaceutical industries. In 2005, Dr. Xu joined Pfizer as a Senior Research Scientist, where she worked until 2009. From 2009 to 2020, she held positions at Profectus BioSciences, Inc, including Director of Immunology and Principal Research Scientist. In 2020, Dr. Xu moved to the Sabin Vaccine Institute as Vice President of Non-Clinical Development, and later as Vice President of Research and Development until 2021. In 2021, she joined Clover Biopharmaceuticals as Senior Vice President of Pre-clinical R&D, and then as Senior Vice President of Vaccine Research until 2022.

Dr. Xu began her education by earning a Doctor of Medicine (MD) degree from Peking University Health Science Center from 1986 to 1991. Dr. Xu then pursued a Ph.D. in Immunology at Weizmann Institute of Science from 1996 to 2001. Dr. Xu furthered her education with a post-doctor training program in Immunology at HHMI at University of Washington from 2001 to 2004.

Dr. Qiubin Lin, Founder and CEO of Delonix, said, "We warmly welcome Dr. Xu to join Delonix Bioworks, bringing with her over 20 years of extensive R&D experience in the field of innovative vaccines. Dr. Xu has been involved in the development of several groundbreaking bacterial vaccines, including those for Staphylococcus aureus, Streptococcus pneumoniae, and Neisseria meningitidis. We believe that Dr. Xu’s expertise will help advance Delonix's innovative bacterial vaccine pipeline to a new strategic development phase.”

Dr. Rong Xu, Chief Scientific Officer of Delnix, said "Delonix boasts a highly innovative vaccine R&D platform and, in a short period, has developed multiple proprietary pipelines. These pipelines are poised to overcome several bottlenecks in traditional bacterial vaccine development through bacterial pathogen genome engineering. I look forward to collaborating with Delonix's dynamic and energetic team to advance its globally leading bacterial vaccine pipeline into the clinical phase, contributing new breakthroughs to the global innovation of bacterial vaccines."

About Delonix

Delonix Bioworks is a leading synthetic biology company specializing in innovative vaccine development. It has advanced gene editing and modification capabilities for over ten pathogens, making it a global leader in genetically engineered vaccine development. The company has significant expertise in engineering key vaccine components, such as polysaccharides, detoxified LPS, and bacterial outer membrane vesicles (OMVs).

The company has launched two proprietary synthetic vaccine platforms: ProBVax, an engineered whole-cell vaccine platform, and BioDVax, an engineered subunit vaccine platform. With these two innovative platforms, Delonix has successfully developed a range of world-class innovative vaccine pipelines, several of which are expected to reach the clinical stage within the next two years.

Since 2021, Delonix has received recognition from various organizations, including the Boehringer Ingelheim Innovation Prize (Champion) and the Venture 50 “New Seed List Top 50”. For more information, please visit: https://delonixbio.com.